NCT05989360 (LUCI-ED) is a NA clinical trial of Lung Clearance Index in Healthy Children, sponsored by Birmingham Women's and Children's NHS Foundation Trust.

Who is sponsoring NCT05989360?

NCT05989360 is sponsored by Birmingham Women's and Children's NHS Foundation Trust.

What drugs are being tested in NCT05989360?

Interventions in NCT05989360: Lung Clearance Index.

What condition does NCT05989360 study?

NCT05989360 studies Healthy Children, Bronchiectasis Adult, Lung Clearance Index.

Is NCT05989360 still recruiting?

NCT05989360 is currently completed. Last updated 14 August 2023.

Last reviewed 2023-08-14 · How we verify

NCT05989360: LUCI-ED

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Utility of Lung Clearance Index in Ethnic Groups and in Disease

Completed NA Last updated 14 August 2023

What this trial tests

NA trial testing Lung Clearance Index in Healthy Children in 85 participants. Completed in 1 September 2022.

Timeline

11 March 2020

Primary endpoint
1 September 2022

1 September 2022

Quick facts

Lead sponsor	Birmingham Women's and Children's NHS Foundation Trust
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	85
Start date	11 March 2020
Primary completion	1 September 2022
Estimated completion	1 September 2022
Sites	1 location across United Kingdom

Drugs / interventions tested

Lung Clearance Index

Conditions studied

Healthy Children — all drugs for Healthy Children →
Bronchiectasis Adult — all drugs for Bronchiectasis Adult →
Lung Clearance Index — all drugs for Lung Clearance Index →

Sponsor

Birmingham Women's and Children's NHS Foundation Trust

Who can join

Adults 6 to 12, any sex, with Healthy Children or Bronchiectasis Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Introduction: Non-CF, non-PCD bronchiectasis in children is a chronic, suppurative lung disease diagnosed by high resolution computed tomography (HRCT) imaging of the lungs. Spirometry can be abnormal in bronchiectasis but has been shown to be insensitive to early disease in other related conditions such as cystic fibrosis. Lung clearance index (LCI) could have a role in assessment of the disease. Lung clearance index is calculated from multiple breath washout tests. There are limited data on the normative values expected using some devices, in a range of ages, and between ethnic groups. The investigators aim to establish normative values in children aged between 6 years and 12 years, to investigate differences between ethnic groups, and to establish the relationship between lung clearance index and other measures of disease in children with bronchiectasis. Methods: Healthy children will be recruited from a range of settings and reviewed to ensure no previous lung disease. Children with bronchiectasis diagnosed on HRCT will be recruited from the outpatient service of Birmingham Children's Hospital. All participants will perform lung function tests including LCI and spirometry. Basic demographic data was collected.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Lung Clearance Index

Trials testing the same drug.

NCT03579173 — Determinants of Early Cystic Fibrosis Lung Disease · completed
NCT03497117 — 19F MRI of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation · EARLY_PHASE1 · terminated

Other recruiting trials for Healthy Children

Currently open trials in the same condition.

NCT06986720 — Urdu Translation of Revised High-Level Mobility Assessment Tool (HiMAT) in Healthy Children · recruiting
NCT07005440 — Functional Training and Dynamic Play Exercise on Gross Motor Skills, Physical Fitness, and Balance in Healthy Children · NA · recruiting
NCT06975982 — Symptoms, Pulmonary Function, Muscle Strength, Exercise Capacity, and Frailty in Esophageal Atresia vs. Healthy Peers · recruiting
NCT06276426 — Plants Optimizing Development Study (PODS) · NA · recruiting
NCT07490587 — To Investigate the Effects of Bifidobacterium Animalis Subsp. Lactis XLTG11 on Growth and Development, Incidence of Alle · Phase 2 · recruiting

Other Birmingham Women's and Children's NHS Foundation Trust trials

Trials by the same sponsor.

NCT05735977 — Nephrogreen. Appearances of Exvivo Renal Tumours Under Near-infrared · NA · completed
NCT05971563 — Amino Acid Kinetics of GMP-AA in Healthy Human Volunteers · NA · completed
NCT05702294 — Electronic Urinary Flowmeter to Improve Accuracy of Bladder Diaries . · NA · completed
NCT04906551 — Measuring Endometrial Blood Flow Using Laser Doppler: Acceptability & Reproducibility · unknown
NCT04854018 — Indo-cyanine Green (ICG) in Paediatric Oncology MIS · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05989360 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Birmingham Women's and Children's NHS Foundation Trust
Last refreshed: 14 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05989360.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing